Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312

Perineuronal nets stabilize the grid cell network

Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940

Cutting edge: long-term B cell memory in humans after smallpox vaccination

Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., & Ahmed, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.4969 · Cited by 695

Looking beyond COVID-19 vaccine phase 3 trials

Kim, J. H., Marks, F., & Clemens, J. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01230-y · Cited by 601

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Outbreak Among Fully Vaccinated Nursing Home Residents Likely Initiated by a Fully Vaccinated Staff Member – Connecticut, July–August 2021

Bart, S. M., Harizaj, A., Pearson, C. L., Conteh, T., Grogan, E. M., Downing, R., Kirking, H. L., Tate, J. E., Jernigan, J. A., & Leung, V. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1025 · Cited by 5

How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022

Althaus, T., Overton, C. E., Devaux, I., House, T., Lapouze, A., Troel, A., Vanzo, B., Laroche, M., Bordero, A., Jorgensen, P., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03444-6 · Cited by 5

Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platformPreprint

Tong, X., Kellman, B. P., Avendaño, M. J., Mendu, M., Hsiao, J. C., Serrano, E. F., García‐Salum, T., Muena, N. A., Pardo‐Roa, C., Morales, M., et al. (2024) · medRxiv · doi:10.1101/2024.10.17.24315607 · Cited by 5

Health disparities in diabetes treatment: The challenge of G6PD deficiency

Israel, A., Raz, I., Green, I., Golan‐Cohen, A., Berkovitch, M., Magen, E., Vinker, S., & Merzon, E. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111965 · Cited by 5

Atovaquone/proguanil use and zoster vaccination are associated with reduced Alzheimer’s disease risk in two cohorts: implications for a latent Toxoplasma gondii mechanism

Israel, A., Weizman, A., Israel, S., Ashkenazi, S., Vinker, S., Magen, E., & Merzon, E. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106473 · Cited by 4

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

Zerbo, O., FIREMAN, B. H., & Klein, N. P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1984891 · Cited by 4

Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model

Uematsu, T., Takano, T., Matsui, H., Kobayashi, N., Ōmura, S., & Hanaki, H. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-023-00623-0 · Cited by 8

National epidemiological analysis of the association of COVID-19 vaccination and incidence of COVID-19 cases in Canada, January to August 2021

Coverage, V., System, I., & Surveillance, V. E. (2023) · Canada Communicable Disease Report · doi:10.14745/ccdr.v49i04a07 · Cited by 4

Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care.

Ticinesi, A., Nouvenne, A., Parise, A., Prati, B., & Meschi, T. (2022) · PubMed Central · doi:10.23750/abm.v93i2.12717 · Cited by 4

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

Joseph, G., Klein, E., Lustig, Y., Weiss-Ottolenghi, Y., Asraf, K., Indenbaum, V., Amit, S., Kriger, O., Gilboa, M., Levy, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10111954 · Cited by 5

Vaccine Effectiveness Against COVID19-Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021Preprint

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000559 · Cited by 4

Systematic screening identifies medication and disease factors associated with schizophrenia risk

Israel, A., Weizman, A., Israel, S., Stokar, J., Ashkenazi, S., Vinker, S., Magen, E., & Merzon, E. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106135 · Cited by 3

Surfing Corona waves – instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy

Kalk, A., Sturmberg, J. P., Damme, W. V., Brown, G. W., Ridde, V., Zizi, M., & Paul, É. (2022) · F1000Research · doi:10.12688/f1000research.110593.1 · Cited by 3

Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study

Li, J., Xie, H., Chen, W., Chen, M., Bai, S., Zhao, W., Zhou, T., Gao, P., Zhang, L., Wang, Q., et al. (2022) · Vaccines · doi:10.3390/vaccines10101677 · Cited by 3

A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers After Vaccination in a COVID-19 Convalescent Population

Hsu, F.-C., Pan, L., Huang, Y., Yang, C.-H., Shiu, M., & Lin, H. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad431 · Cited by 3

Risk factors for SARS-CoV-2 infection: a test-negative case–control study with additional population controls in Norway

Sarjomaa, M., Zhang, C., Tveten, Y., Kersten, H., Reiso, H., Eikeland, R., Kongerud, J. S., Berg, K. K., Thilesen, C., Nordbø, S. A., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-073766 · Cited by 3

Duration of protective immunity following COVID‐19 vaccination of individuals with underlying health conditions: A rapid review

Walsh, K. A., O’Donnell, H., O’Loughlin, M., Eames, H., Jiang, J., O’Brien, K. M., Broderick, N., O’Brien, K. K., Carrigan, M., Comber, L., et al. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2504 · Cited by 3

Comparative Analysis of Inflammatory Bowel Disease Management

Israel, A., Sharif, Κ., Zada, G., Friedenberg, A., Vinker, S., & Lahat, A. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002088 · Cited by 3

Why we may need to rethink future SARS-CoV-2 vaccination strategies

Klimek, P. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100214 · Cited by 3

Determinants of the willingness to get the third COVID-19 vaccine dose among health care workers

Paris, C., Saade, A., Tadié, É., Van, R. N., Turmel, V., Garlantézec, R., & Tattevin, P. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.04.007 · Cited by 3

Risk factors for critical forms of SARS-CoV-2 infection in fully vaccinated patients: a prospective observational study

Bou-ouhrich, Y., & Charra, B. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.43.124.32265 · Cited by 3

The dangers in policy and practice of following the consensus

Abbasi, K. A. (2021) · BMJ · doi:10.1136/bmj.n2885 · Cited by 3

Timing of BNT162b2 vaccine prior to COVID ‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study

Gutwein, O., Tzarfati, K. H., Apel, A., Rahimi‐Levene, N., Levy, I., Tadmor, T., & Koren‐Michowitz, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6397 · Cited by 3

Post-Mrna Vaccination SARS-CoV-2 IGG Concentrations and Surrogate Virus Neutralization Response Compared by HIV Status and Type of Vaccine: A Matched Case-Control Observational StudyPreprint

Spinelli, M. A., Peluso, M. J., Lynch, K. L., Yun, C. A., Glidden, D. V., Henrich, T. J., Deeks, S. G., & Gandhi, M. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909785 · Cited by 3

Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World DataPreprint

Reynolds, S. L., Kaufman, H. W., Meyer, W. A., Bush, C., Cohen, O. J., Cronin, K. A., Kabelac, C. A., Leonard, S., Anderson, S., Petkov, V. I., et al. (2022) · medRxiv · doi:10.1101/2022.02.25.22271515 · Cited by 3

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Long-Term Risk of Immune-Related diseasesPreprint

Israel, A., Schäffer, A. A., Berkovitch, M., Ozeri, D. J., Merzon, E., Green, I., Golan‐Cohen, A., Ruppin, E., Vinker, S., & Magen, E. (2023) · medRxiv · doi:10.1101/2023.03.23.23287616 · Cited by 3

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study

Djordjević, N., Matić, S. L., Milovanovic, D. R., Stefanović, S., Popović, S., Todorovic, D., Djurdjevic, P. M., Sazdanovic, P. S., Antic, V., Lončar, S., et al. (2023) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh221217082d · Cited by 2

COVID-19 Vaccines and COVID-19 in People Living with HIV

Karaşın, M. F., Bayraktar, Z., Deniz, M. T., Akhan, S., & Özdemir, M. (2024) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2024.271 · Cited by 2

Estimation of trajectory of COVID-19 vaccines effectiveness against infection

Jiang, J., Lam, K. F., Lau, E. H. Y., Yin, G., Lin, Y., & Cowling, B. J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127067 · Cited by 2

Identification and Estimation of Vaccine Effectiveness in the Test-Negative Design Under Equi-confounding

Boyer, C., Li, K. Q., Shi, X., & Tchetgen, E. J. T. (2025) · Epidemiology · doi:10.1097/ede.0000000000001926 · Cited by 4

Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 2

SARS-CoV-2 Infection-Blocking Immunity Post Natural Infection: The Role of Vitamin D

Fanne, R. A., Moed, M., Kedem, A., Lidawi, G., Maraga, E., Mohsen, F., Roguin, A., & Meisel, S.-R. (2023) · Vaccines · doi:10.3390/vaccines11020475 · Cited by 2

The impact of vaccinating adolescents and children on COVID-19 disease outcomesPreprint

Ainslie, K. E. C., Backer, J. A., de Boer, P., van Hoek, A. J., Klinkenberg, D., Altes, H. K., Leung, K. Y., de Melker, H. E., Miura, F., & Wallinga, J. (2021) · medRxiv · doi:10.1101/2021.10.21.21265318 · Cited by 2

Vitamin D Deficiency, Supplementation, and Aging‐Related Morbidity and Mortality Across Two Longitudinal Population Cohorts

Israel, A., Weizman, A., Israel, S., Ashkenazi, S., Ruppin, E., Magen, E., Merzon, E., & Vinker, S. (2026) · Aging Cell · doi:10.1111/acel.70752 · Cited by 1

Humoral response dynamics following inactivated SARS-CoV-2 vaccination and their association with subsequent infection and symptoms in individuals with and without prior SARS-CoV-2 infection: evidence from Sichuan Province, China

Yu, Y., Jia, M., Zhong, J., Feng, L., Jiang, X., Li, Y., Huang, Q., Chen, Y., Wang, X., Yue, Y., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02191-24 · Cited by 1

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination

Israel, A., Merzon, E., Shenhar, Y., Green, I., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2022) · Vaccines · doi:10.3390/vaccines10050636 · Cited by 1

Immunity and COV ID-19 vaccines. Revisiting the bases

Ruiz-Romero, J. A., Quijano-Castro, F. O., López-Romero, R., Chavarría-Arriaga, X., Torres, M., & Salcedo, M. (2022) · Gaceta Médica de México · doi:10.24875/gmm.22000092 · Cited by 5

Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease

Sugiura, T., Sugiura, H., Kato, H., Nariai, Y., Mizumoto, Y., Hanada, K., Takahashi, R., Hinotubo, Y., Tanaka, N., Sasaki, M., et al. (2022) · Infectious Disease Reports · doi:10.3390/idr15010003 · Cited by 1

Analyse épidémiologique nationale portant sur l'association entre la vaccination contre la COVID-19 et l'incidence des cas de COVID-19 au Canada, de janvier à août 2021

Agence de la santé publique du Canada, É. D. L. S. D. L. C.-1. (2023) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v49i04a07f · Cited by 1

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers

Rasheed, W. S., & Sarkees, A. N. (2023) · Medicine · doi:10.1097/md.0000000000035444 · Cited by 1

Immunogenicity of BNT162b2 vaccine after two and three doses in health personnel and institutionalized elderly people not infected with SARS-CoV-2

Rodríguez-Prieto, M., Modino-García, F., de la Arada-Benavides, C., de la Puente, R., Carvajal, A., Rodríguez-Cabañeros, I., de Prado-Santos, C., de Mota-Luna, B., Fernández‐Villa, T., Fernández-Vázquez, J. P., et al. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102092 · Cited by 2

Bilateral Perivascular Chorioretinal Atrophy Resembling Pigmented Paravenous Chorioretinal Atrophy Post COVID-19 Infection: A Case Report and Comprehensive Immune Profiling

Sato, T., Takenaka, Y., & Takeuchi, M. (2024) · Vaccines · doi:10.3390/vaccines12080878 · Cited by 1

Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients

Xu, C., He, Z., Lei, W., Zhu, J., Zhao, D., Kong, J., Yao, W., Xu, Y. M., & Huang, J. (2023) · The Clinical Respiratory Journal · doi:10.1111/crj.13590

COVID-19 Neutralizing Antibody Surveillance Testing for Fully Vaccinated Individuals During Delta Variant SpreadPreprint

Pan, J., Li, Z., Wang, L., Szymanski, J., Romano, M. J. E., Yin, D., Wang, A., Small, T., Zou, Z., Li, J., et al. (2021) · medRxiv · doi:10.1101/2021.10.01.21264371 · Cited by 1

Real-time monitoring of the effectiveness of six COVID-19 vaccines in Hungary in 2021 using the screening methodPreprint

Krisztina, H. J., Ferenci, T., Ferenczi, A., Túri, G., Röst, G., & Oroszi, B. (2022) · medRxiv · doi:10.1101/2022.02.18.22271179 · Cited by 1

Individuals with recent prior SARS-CoV-2 infection are at reduced risk of Omicron infection and associated hospitalizationPreprint

Nadig, M., Niesen, M. J. M., Lenehan, P. J., Agarwal, V., Ross, J., Ardhanari, S., Venkatakrishnan, A., & Soundararajan, V. (2022) · medRxiv · doi:10.1101/2022.08.10.22278641 · Cited by 1

Anti-tetanus vaccination is associated with reduced occurrence and slower progression of Parkinson’s diseasePreprint

Israel, A., Magen, E., Merzon, E., Ruppin, E., Vinker, S., & Giladi, N. (2024) · medRxiv · doi:10.1101/2024.05.03.24306800 · Cited by 1

Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced Alzheimer’s Disease Risk in Two Cohorts: Implications for a Latent Toxoplasma gondii MechanismPreprint

Israel, A., Weizman, A., Israel, S., Ashkenazi, S., Vinker, S., Magen, E., & Merzon, E. (2025) · medRxiv · doi:10.1101/2025.03.07.25323566 · Cited by 1

Antiprotozoal medications associated with increased longevity and reduced morbidity in two national cohortsPreprint

Israel, A., Weizman, A., Israel, S., Ashkenazi, S., Ruppin, E., Vinker, S., Magen, E., & Merzon, E. (2025) · medRxiv · doi:10.1101/2025.07.01.25330644 · Cited by 1

SARS-CoV-2 epidemic in the South American Southern cone: can combined immunity from vaccination and infection prevent the spread of Gamma and Lambda variants while easing restrictions?Preprint

Fiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2021) · medRxiv · doi:10.1101/2021.09.16.21263701v1

Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?

Ogura, W., Ohtsuka, K., Matsuura, S., Okuyama, T., Matsushima, S., Yamasaki, S., Miyagi, H., Sekiguchi, K., Ohnishi, H., & Watanabe, T. (2022) · Viruses · doi:10.3390/v14050956

Vaccines, Variants, and Vigilance: Strengthening the Coronavirus Disease 2019 (COVID-19) Public Health Response Through Partnerships and Collaborations

Kutty, P. K., Stuckey, M. J., & Koumans, E. H. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac522

Prophylactic Effect of Ivermectin on SARS-CoV-2 Induced Disease in a Syrian Hamster ModelPreprint

Uematsu, T., Takano, T., Matsui, H., Kobayashi, N., & Hanaki, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2012940/v1

Surfing Corona waves – instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy

Kalk, A., Sturmberg, J. P., Damme, W. V., Brown, G. W., Ridde, V., Zizi, M., & Paul, É. (2022) · F1000Research · doi:10.12688/f1000research.110593.2 · Cited by 1

COVID-19: Epidemiology, Etiology, Clinical Manifestations, Diagnosis, Therapeutic Options, and Prevention

Mogollon, J., Halaseh, G., & Swaminathan, N. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-28536-3_1

Surfing Corona waves – instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy

Kalk, A., Sturmberg, J. P., Damme, W. V., Brown, G. W., Ridde, V., Zizi, M., & Paul, É. (2023) · F1000Research · doi:10.12688/f1000research.110593.3

Short-term SARS-CoV-2 Re-infection Rate in Vaccinated Health Workers based on Received Vaccines: A Cross-sectional Study

Sinaei, R., Jafari, M., Karamozian, R., Pezeshki, S., Sinaei, R., Robati, F. K., Yeganeh, M. H., & Najafzadeh, M. J. (2023) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x19666230911094423

Technocratic Feudalism, Digital Apartheids, and the New Surveillance Governance

Briggs, D., Telford, L., Lloyd, A., & Ellis, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-41866-2_4

Analysis of Potential Risk Factors of COVID-19 Based on Variants: Omicron, Delta, and Alpha

Kannan, D., Muppiri, S., & Reid, M. (2023) · Archives of Clinical and Biomedical Research · doi:10.26502/acbr.50170375

Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey

Feng, H., Chen, J., Sun, J., & Jiang, Y. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100508 · Cited by 1

Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Jameie, M., Looha, M. A., Ebadi, Z., Amanollahi, M., Amani, K., Nobahari, F., Abdollahi, A., Mousavi, M., Pourghaz, B., & Harirchian, M. H. (2024) · BMC Neurology · doi:10.1186/s12883-024-03793-y · Cited by 1

Omicron-COVID-19-Related Knowledge in Parkinson’s Disease Patients and Their Caregivers: A Cross-sectional Study

Dhiman, N. R., Gyanpuri, V., Kumar, A., & Joshi, D. (2024) · Annals of Neurosciences · doi:10.1177/09727531241284359

Anti-Tetanus Vaccination Is Associated with Reduced Occurrence and Slower Progression of Parkinson’s Disease—A Retrospective Study

Israel, A., Magen, E., Ruppin, E., Merzon, E., Vinker, S., & Giladi, N. (2024) · Biomedicines · doi:10.3390/biomedicines12122687

Systematic Screening of Prior Medication Use Reveals Protective Associations Against Schizophrenia Linked to Toxoplasma gondii -Targeting AgentsPreprint

Israel, A., Weizman, A., Israel, S., Stokar, J., Ashkenazi, S., Vinker, S., Magen, E., & Merzon, E. (2025) · medRxiv · doi:10.1101/2025.02.14.25322266

Proton pump inhibitors and upper gastrointestinal cancer: a matched case-control study addressing confounding by indicationPreprint

Sawaid, I. O., Din, Z., Golan, E., Ruppin, E., Golan‐Cohen, A., Green, I., Merzon, E., Vinker, S., Samson, A. O., & Israel, A. (2025) · medRxiv · doi:10.1101/2025.06.13.25329558

Additional file 1 of How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022

Althaus, T., Overton, C. E., Devaux, I., House, T., Lapouze, A., Troel, A., Vanzo, B., Laroche, M., Bordero, A., Jorgensen, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25980533

Comorbidities and healthcare utilization rates among migraine patients compared to matched controls: Real-world data

Shifrin, A., Domany, E., Davidovici, D., Tirosh, M., Bareket‐Samish, A., Vinker, S., & Israel, A. (2026) · Cephalalgia Reports · doi:10.1177/25158163251414041

Antiprotozoal drug exposure and reduced long-term mortality and morbidity: a multi-cohort pharmacoepidemiologic study

Israel, A., Weizman, A., Israel, S., Ashkenazi, S., Ruppin, E., Vinker, S., Magen, E., & Merzon, E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1861376

Incidence of Positive Severe Acute Respiratory Syndrome Coronavirus Polymerase Chain Reaction After Coronavirus Disease 2019 Vaccination With up to 8 Months of Follow-up: Real-life Data From the Capital Region of Denmark

Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9

Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMOPreprint

Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · medRxiv · doi:10.1101/2021.09.01.21262957 · Cited by 7

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · Emerging infectious diseases · doi:10.3201/eid2802.211834 · Cited by 32

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Glatman‐Freedman, A., Bromberg, M., Hershkovitz, Y., Sefty, H., Kaufman, Z., Dichtiar, R., & Keinan‐Boker, L. (2022) · Emerging infectious diseases · doi:10.3201/eid2805.220141 · Cited by 26

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Spitzer, A., Angel, Y., Marudi, O., Zeltser, D., Saiag, E., Goldshmidt, H., Goldiner, I., Stark, M., Halutz, O., Gamzu, R., et al. (2022) · JAMA · doi:10.1001/jama.2021.23641 · Cited by 97